替米沙坦对高血压合并糖调节受损患者的影响

目的：探讨替米沙坦对高血压合并糖调节受损患者的影响。方法：入选初诊为原发性高血压合并糖调节受损患者90例为研究对象，随机分为两组，观察组45例每天服用替米沙坦40～80mg，对照组45例每天服用厄贝沙坦75～150mg，共治疗12周。观察高血压患者治疗前后血压（BP）、空腹血糖（FPG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbA1c）、空腹胰岛素（FINS）和胰岛素抵抗指数（IRI）水平的变化。结果：两组治疗后收缩压和舒张压均明显下降，与治疗前相比差异有统计学意义（P＜0.05）。两组BP治疗后比较差异无统计学意义（P＞0.05）。与对照组比较，观察组治疗后FPG、2hPG、HbA1c、FINS和IRI水平明显改善，两组比较差异有统计学意义（均P＜0.05）。结论：替米沙坦可改善高血压合并糖调节受损患者的糖代谢。

Influence of telmisartan on the impaired glucose regulation in patients with hypertention

Objective： To explore the inlfuence of telmisartan on the impaired glucose regulation （IGR） of patients with hypertention.Methods： Ninety patients with IGR and hypertension who were selected in our hospi-tal were randomly divided into two groups. The patients in study group （45 cases） were treated by taking telmis-artan 40~80 mg per day for 12 weeks and the patients in control group （45 cases） were required to take irbesartan 75~150 mg per day for 12 weeks. Their blood pressure （BP） and the insulin sensitivity including fasting plasma glucose （FPG）, 2 hours postprandial glucose （2hPG）, glycosylated hemoglobin, fasting insulin （FINS） and insulin resistance index （IRI） were observed and analysed after 12 weeks.Results： Systolic blood pressure （SBP） and diastolic blood pressure （DBP） decreased signiifcantly in both groups after treatment （P〈0.05）. Compared with the control group, FBG, 2hPG, HbA1c, FINS and IRI in the study group decreased after telmisartan treatment （P〈0.05）.Conclusion： Telmisartan can effectively improve glucose metabolism in the patients with IGR and hypertension.